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Abstract
Tuberous sclerosis complex (TSC) is a neurocutaneous disorder characterized by multiple symptoms including
neuropsychological deficits such as seizures, intellectual disability, and autism. TSC is inherited in an autosomal
dominant pattern and is caused by mutations in either the TSC1 or TSC2 genes, which enhance activation of the
mammalian target of rapamycin (mTOR) signaling pathway. Recent studies have suggested that mTOR inhibitors
such as rapamycin can reverse TSC-associated deficits in rodent models of TSC. In addition, clinical trials are
ongoing to test the efficacy of mTOR inhibitors toward the psychiatric symptoms associated with TSC. Here, we
report a case study of a Korean patient with TSC, who exhibited multiple symptoms including frequent seizures,
intellectual disability, language delays, and social problems. We performed whole exome sequencing and identified
a novel small deletion mutation in TSC2. Expressing the novel deletion mutant in HEK293T cells significantly
increased mTOR pathway activation. Furthermore, everolimus treatment showed not only reduction in SEGA size,
but dramatically improved behavioral deficits including autism related behaviors in the patient. In summary, we
identified a novel small deletion mutation in TSC2 associated with severe TSC in a Korean family that enhances the
activation of mTOR signaling in vitro. Everolimus treatment improved behavioral deficits in the patient.
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Introduction
Tuberous sclerosis complex (TSC) is a genetic disorder
characterized by the presence of benign hamartomas in
any organ system, with highly variable, unpredictable,
and potentially devastating neurological outcomes [1, 2].
TSC is the second most common identified neuro-
cutaneous disorder with an estimated incidence of
1:6000, affecting more than 1 million individuals world-
wide [3, 4]. The majority of patients have central ner-
vous system involvement that manifests as structural
brain abnormalities, epilepsy, and cognitive, behavioral,
and psychiatric deficits including autism spectrum dis-
order (ASD) [5, 6]. All types of seizures are seen, often
in combination. Half of individuals have normal
intelligence, but almost none are free from neuropsychi-
atric problems [7]. Importantly, ASD is diagnosed in ap-
proximately 40–60 % of patients with TSC, and TSC
accounts for 3–4 % of ASD [8–10].
TSC is caused by mutations in either of two tumor
suppressor genes, TSC1 or TSC2, encoding hamartin
and tuberin, respectively [11]. TSC is inherited in an
autosomal dominant pattern and haploinsufficiency of
TSC causes neurological phenotypes including learning
disability and social deficits [10, 11]. De novo mutations
account for approximately 80 % of TSC cases. TSC2 mu-
tations are four times as common as TSC1 mutations
among de novo cases, whereas the prevalence of TSC1
and TSC2 mutations is approximately equal among fa-
milial TSC cases [12]. TSC1 and TSC2 mutations lead to
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essentially identical phenotypic manifestations, although
there have been some suggestions that the TSC2 pheno-
type is typically more severe [13, 14]. The TSC1 and
TSC2 proteins act as a heterodimer to suppress mam-
malian target of rapamycin (mTOR), a serine/threonine
protein kinase that regulates cell growth and division [5,
15]. Loss of either TSC1 or TSC2, followed by a “second
hit” of the remaining functional allele thereby preventing
formation of the heterodimeric complex, causes loss of
regulatory control over mTOR and leads to overactive
cell growth and proliferation [1, 16]. Thus, at the cellular
level, loss of TSC1 or TSC2 results in upregulation of
the mTOR pathway [10, 17]. The molecular understand-
ing of the TSC pathophysiology has opened up
possibilities for molecular targeted treatments of the
neuropsychiatric phenotype in TSC using mTOR inhibi-
tors such as rapamycin [16]. Notably, rapamycin treat-
ments have been shown to successfully reverse the
deficits in behavior and synaptic plasticity in rodent
models of TSC [10, 18–20].
Recently, the mTOR inhibitors everolimus and siroli-
mus have been shown to exhibit efficacy for the treat-
ment of several manifestations of TSC such as
subependymal giant cell astrocytomas (SEGA), seizures,
renal angiomyolipomas, lymphangioleiomyomatosis, and
facial angiofibroma lesions in patient with TSC [21–24].
Moreover, human and animal studies suggest that
mTOR inhibitors improve deficits of sociability, learning
and neurodevelopment in TSC mouse models and pa-
tients with TSC [18, 25, 26]. On the basis of these find-
ings, although some clinical trials have been completed
or initiated to test whether everolimus treatment might
improve neurocognition, features of autism, and the
neuropsychological deficits in children with TSC (clini-
caltrials.gov study ID: NCT01289912, NCT01730209), in
the present study we present a case of a family with a
novel TSC2 mutation in which the behavioral pheno-
types of a 3-year-old boy with TSC accompanied by




The proband presented intractable epilepsy and severe
developmental delay. He was born at 38 weeks gestation
by spontaneous vaginal delivery with a birth weight of
2.4 kg after an uncomplicated pregnancy. At the age of
13 months, he experienced his first episode of febrile
status epilepticus with a duration of 40 min; at
17 months, a second episode of febrile status epilepticus
persisted for more than an hour. Subsequently, he had
frequent seizures with or without fever, and was often
admitted with status epilepticus. Physical examination
identified scattered hypopigmented lesions on the trunk
(Fig. 1a). Brain magnetic resonance imaging (MRI) re-
vealed a SEGA (Fig. 1b), cortical tubers and subependy-
mal nodules consistent with TSC (Fig. 1c). The seizures
persisted despite the use of vigabatrin and levetiracetam
at the maximum tolerated doses.
A baseline psychomotor developmental evaluation was
performed when the patient was 45 months of age. The
Denver Developmental Screening Test (DDST-II) revealed
delayed development in areas of fine motor-adaptive,
personal-social, and language skills by 25 months on aver-
age. He was not able to get a score in any subtests in the






Fig. 1 Cutaneous features and brain MRI findings of the patient. a
Photographs showing several hypopigmented macules on the chest
and abdomen (left) and on the back (right) of the patient. b-c.
Pre-treatment brain MRI revealing a SEGA (white arrow) located at
the foramen of Monro within on coronal T2-weighted imaging (b),
multiple cortical tubers (white arrowheads) and a subependymal
nodule (black arrowhead) within on axial T2-weighted imaging (c).
d-e Post-treatment brain MRI demonstrating size reduction of the
SEGA (white arrow) (d), reduced cortical tubers (white arrowheads)
and the same size of subependymal nodule (black arrowhead)
(e) compared to pre-treatment MRI
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(WPPSI-III). His social age was 22 months and social quo-
tient was 49.8 by the Social Maturity Scale (SMS). The
Childhood Autism Rating Scale (CARS) and Autism Diag-
nostic Observation Schedule-2 (ADOS-2) showed scores
of 35.5 and 20, respectively, which were above the cutoff
scores for a diagnosis of autism. His Autism Diagnostic
Interview-Revised (ADI-R) scores were also above the aut-
ism diagnostic cutoffs in each criterion; 24 in qualitative
abnormalities in reciprocal social interaction, 18 for verbal
and 12 for non-verbal in qualitative abnormalities in com-
munication, and 5 in repetitive/stereotyped patterns of be-
havior. The speech and language evaluation revealed that
his receptive and expressive language was delayed by
27 months. Other evaluations including ophthalmologic
examination, dental examination, ultrasonography and
electrocardiography (ECG) of the heart, high resolution
computed tomography (HRCT) of the chest, blood pres-
sure, abdominal MRI, and glomerular filtration rate (GFR)
testing demonstrated no abnormalities. Evaluations for the
diagnosis of TSC and the respective findings are listed in
Table 1.
Identification of a small deletion variant located in TSC2
by whole exome sequencing
In the family, three individuals including the grand-
mother (I-1), father (II-1), and the proband (third son,
III-2) met diagnostic criteria for TSC. Definite diagnosis
is made by 2 major features or 1 major feature with 2 or
more minor features; the grandmother (I-1) and father
(II-1) had 3 major features: multiple hypomelanotic mac-
ules, angiofibromas, and ungual fibromas. The other
family members (including II-2, III-1 and III-3) had no
features of TSC (Fig. 2a). In contrast to the proband (III-
2), the grandmother (I-1) and father (II-1) had normal
intelligence and epilepsy or neuropsychiatric symptoms
were not identified.
To confirm a TSC gene mutation, we performed whole
exome sequencing for the six family members, generat-
ing over 50 million reads (average mean target depth:
65×). In each family member, about 80,000 variants were
identified in RefSeq exonic regions. After filtering com-
mon variants (see Methods), over 500 variants causing
non-synonymous changes, frameshifts, or which were lo-
cated near splicing sites were identified in each family
member. To identify rare and novel causative candidate
variants, we selected the variants that were detected in
affected (I-1, II-1, and III-2) but not unaffected family
members (II-2, III-1, and III-3). A total of 14 variants
were identified, five of which were novel (i.e., not re-
ported in dbSNP142) (Additional file 1: Table S1).
Among those five, a variant in GLI2 (NM_004270),
c.C2740T (p.R914W) was predicted as deleterious by
three different tools (SIFT, PolyPhen-2, and MutationTa-
ster) commonly used to predict the possible impact of
amino acid changes. GLI2 is known as a Kruppel-like
transcription factor and is associated with cancer pro-
gression and metastasis [27]. Notably, one of the novel
variants was located in the TSC2 gene, the mutation of
which causes TSC [28] and in which over 700 mutations
have been reported [29]. We confirmed that only the af-
fected family members (I-1, II-1, and III-2) carried the
variant, identified as a small c.700–701 deletion (chr16:
2106697-2016698) by Sanger sequencing (Fig. 2b). The
small deletion variant is located in the TSC1 binding do-
main and the flanking region of the variant is highly
conserved across different species (Fig. 2c). We pre-
dicted that the deletion could generate a truncated form
of the TSC2 protein because of the introduction of a
premature termination codon.




Brain Brain MRI Multiple cortical tubers,
subependymal nodules and a
SEGA
EEG Runs of spikes in right fronto-
polar region
DDST-II Delayed development in areas
of fine motor-adaptive,
personal-social, and language
skills by 25 months on average
WPPSI-III Could not get a score in any
subtest
CARS 35.5











Teeth Detailed dental exam Unremarkable
Skin Detailed skin exam Scattered hypopigmented
lesions
Heart Ultrasonography Small muscular ventricular
septal defect (VSD) in the




Lung HRCT of chest No lymphangioleiomyomatosis
(LAM)
Kidney Blood pressure Normal
Abdominal MRI No angiomyolipoma or renal
cyst
GFR test Normal
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Everolimus treatment rescued abnormal mTOR pathway
activation by the novel TSC2 frameshift mutation
To investigate the effect of the novel frameshift muta-
tion of TSC2 on mTOR pathway activation, we per-
formed a transfection-based immunoblot assay [30, 31].
As predicted, the novel TSC2 c.700–701 deletion mutant
was detected as an approximately 37 kDa-sized band,
whereas the wild-type TSC2 was detected as an approxi-
mately 200 kDa-sized band on the blot owing to the
frameshift resulting in a premature termination of trans-
lation (Fig. 3a). The expression level of TSC2 p.R611Q
mutant and c.700–701 deletion mutant was reduced
compared to TSC2 wild-type (WT: 1.000 ± 0.049, TSC2
p.R611Q mutant: 0.455 ± 0.065, TSC2 c.700–701 dele-
tion mutant: 0.040 ± 0.069, One-way ANOVA followed
by Dunnett’s test, all p <0.0001, n = 9, Fig. 3a and b).
Furthermore, the expression level of TSC1 was also re-
duced compared to that of TSC1 co-transfected with
wild-type TSC2 despite the same quantity of TSC1 DNA
construct was transfected (pcDNA3.1(+): 0.367 ± 0.141,
WT: 1.000 ± 0.041, TSC2 p.R611Q mutant: 0.161 ± 0.061,
TSC2 c.700–701 deletion mutant: 0.247 ± 0.100, One-
way ANOVA followed by Dunnett’s test, all p < 0.0001,
n = 9, Fig. 3a and c), which is consistent with previous
reports [30, 31]. In contrast, the phospho-S6K (T389)






TSC2 c.700_701del, p.E234fs (NM_000548)
TSC1BD GAP
p.E234fs
















chr16: 2106697-2016698 chr16: 2106697-2016698
Fig. 2 Identification of a small deletion variant in the TSC2 gene. a Pedigree of the affected family. Closed symbols represent affected family members
(I-1, II-1, and III-2). Whole exome sequencing was performed for six family members (I-1, II-1, II-2, III-1, III-2, and III-3). b Confirmation of the identified
small deletion variant in the TSC2 gene. The two nucleotide deletion (c.700–701del, chr16: 2106697–2016698) identified in the three affected members
was validated by Sanger sequencing of the genomic DNA from six family members. The TSC2 transcript, NM_000548 (RefSeq sequence) with the two
nucleotide deletion (c.700–701del; cDNA position 700 and 701) could be translated into a truncated form of the TSC2 protein because of the frameshift
at the amino acid position 234, glutamic acid (p.E234fs). c Schematic diagram of the TSC2 protein with the position of the small deletion identified in
this study. The variant is located in the TSC1 binding domain (TSC1BD, orange); it is predicted that the variant generates a premature stop codon in
the TSC1BD domain. An amino acid multiple sequence alignment of the region near the small deletion for eight different species shows that the
region is evolutionally highly conserved. GAP GTPase activating protein domain
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group compared to control wild-type group (WT: 1.000
± 0.034, TSC2 c.700–701 deletion mutant: 1.343 ± 0.145,
One-way ANOVA followed by Dunnett’s test, p <0.05, n
= 9, Fig. 3a and d), suggesting that the expression of the
TSC2 c.700–701 deletion mutant results in hyperactiva-
tion of the mTOR signaling pathway [30].
Next, to investigate whether an mTOR inhibitor could
rescue elevated mTOR pathway activation by the novel
TSC2 frameshift mutation, we treated 10 nM everolimus to
the TSC2-transfected HEK293Tcell cultures and performed
immunoblot assays. Everolimus significantly reduced the el-
evated phospho-S6K (T389) level in p.R611Q mutant group
(4.096 ± 0.884 to 0.637 ± 0.156, One-way ANOVA followed
by Bonferroni’s test, p <0.01, n = 3) and novel TSC2 mutant
group (4.285 ± 0.343 to 0.639 ± 0.114, One-way ANOVA
followed by Bonferroni’s test, p <0.01 n = 3, Fig. 4a & b).
The phospho-S6K (T389) level in the everolimus-treated
wild-type group was not significantly reduced (1.000 ±
0.241 to 0.693 ± 0.022, One-way ANOVA followed by Bon-








































































































































































Fig. 3 Immunoblot analysis of mTOR pathway activation by TSC2 mutants. a Representative immunoblot of S6K1 phosphorylation by novel frameshift
TSC2 c.700–701 deletion (del) mutant expression. Note that the c.700–701 del mutant is detected as an approximately 37 kDa-sized band, whereas the
wild-type TSC1 is detected as an approximately 200 kDa-sized band. b. Relative expression levels of TSC2 mutants in the presence of wild-type TSC1
(One-way ANOVA followed by Dunnett’s test, *** p <0.001). c Mean TSC1 expression levels in the presence of empty vector and TSC2 mutants relative
to wild-type TSC2 (One-way ANOVA followed by Dunnett’s test, *** p <0.001). d Mean phospho-S6K levels generated by TSC2 variants’ expression
relative to wild-type TSC1-TSC2 expression (One-way ANOVA followed by Dunnett’s test, * p <0.05). All data are shown as the mean ± SEM of nine
independent experiments
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Everolimus dosing and tolerability
Confirming that the mutation caused hyperactivation
of mTOR signaling encouraged us to treat the patient
with the mTOR inhibitor everolimus. Everolimus was
thus administered when the patient was 45 months of
age. The body surface area was 0.86 m2 and the me-
dian maintenance dose of everolimus was 5.81 mg/
m2/day. Serum levels during the maintenance dose
were between 5 and 15 ng/mL. During the study, the
patient exhibited aggression and irritability for several
weeks. No severe or life-threatening side effects re-
lated to treatment occurred. The patient recovered
without dose adjustment and was able to continue
everolimus treatment.
Everolimus treatment reduced size of SEGA
There was a size reduction of SEGA on post-treatment
brain MRI after 4 months compared to baseline. Pre-
treatment coronal T2-weighted imaging shows a 1.5 cm
sized hypointense SEGA located at the foramen of
Monro (Fig. 1b). Post-treatment coronal T2-weighted
imaging reveals a reduced size of SEGA with a max-
imum diameter of 1.1 cm (Fig. 1d).
Multiple cortical tubers and a subependymal nodule
within on pre-treatment MRI (Fig. 1c) demonstrated re-
duced cortical tubers and the same size of subependymal
nodule in post-treatment MRI (Fig. 1e).
Everolimus treatment reduced seizure frequency and
duration
After treatment with everolimus, the seizure fre-
quency and duration in the patient was significantly
reduced. Vigabatrin and levetiracetam were withdrawn
by the parents 1 month after treatment and the
patient was seizure free for more than 3 months.
Although seizures occasionally recurred during treat-
ment with everolimus for which vigabatrin was ad-
ministered, the median seizure frequency was
decreased by 90 % (pre- vs. post-treatment, 21 vs. 2
seizures per week) and the median seizure duration
was also decreased by 98 % (600 vs. 10 s) compared
to that prior to everolimus treatment (Fig. 5a). In
addition, electroencephalography (EEG) showed run
of spikes in the right fronto-polar region prior to
everolimus treatment, whereas no epileptiform dis-








































































































Fig. 4 Rescue of elevated mTOR pathway activation by everolimus treatment. a Representative immunoblot of reduced S6K1 phosphorylation by
everolimus treatment. b Mean phospho-S6K levels generated by TSC2 variants’ expression relative to wild-type TSC1-TSC2 expression in the presence
of vehicle (DMSO) or everolimus (One-way ANOVA followed by Bonferroni’s test, ** p <0.01). All data are shown as the mean ± SEM of three
independent experiments
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Everolimus treatment improved general behavioral
deficits and autistic phenotypes
Everolimus treatment had a great impact on reducing
behavioral deficits and improved cognition, attention,
social interaction, and language development in the pa-
tient. Just 1 day after the initiation of treatment, he
started to understand and follow some verbal com-
mands. After several days, episodes of urinary incontin-
ence no longer occurred and the patient urinated in the
toilet for the first time. Repetitive motions such as sway-
ing or twirling and obsession with running water disap-
peared. At 1 month after treatment, the patient began to
use two words sentences.
The parents were also asked to provide the Autism
Treatment Evaluation Checklist (ATEC) scores prior to
and after 1 year of the intervention. The ATEC has been
successfully used to measure treatment effects and pro-
gress over time in several studies on ASD [32–34]. Fol-
lowing the initiation of treatment, the ATEC score was
markedly decreased indicating a decrease in severity of
ASD symptoms (Fig. 5b). Subscale totals more than 104
are considered to indicate very severe autism as they are
in the 90th percentile; patients with scores less than 50
are considered to have good chances of being semi-
independent and are within the 30th percentile level. A





Median seizure frequency 21 seizures per week Post-
treatment




Fig. 5 Effect of everolimus treatment on seizure and general behavioral features. a The median seizure frequency and duration decreased
compared to that prior to everolimus treatment. EEG showed run of spikes in the right fronto-polar region prior to everolimus treatment (left side),
whereas no epileptiform discharge was observed following treatment (right side). b In the evaluation of the improvement in general and autistic
behavioral features, ATEC showed a decrease in the scores in all four categories (Speech/Language/Communication, Sociability, Sensory/Cognitive
awareness, and Health/Physical/Behavior) after everolimus treatment compared to pre-treatment
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represent marked improvement following autism treat-
ment. Here, the subscale totals of the patient decreased
from 127 prior to treatment to 44 following treatment
initiation; substantial decreases were observed following
treatment initiation in all four of the ATEC categories.
The Speech/Language/Communication ATEC scores de-
creased from 23 prior to treatment to 11 following treat-
ment initiation; Sociability ATEC scores decreased from
36 to 10; Sensory/Cognitive Awareness ATEC scores de-
creased from 34 to 15; and the Health/Physical/Behavior
ATEC scores decreased from 32 to 8. The efficacy of
everolimus on general and autistic behavioral deficit
were not diminished over up to 2 days without medica-
tion, but it remains to be systematically determined how
long the effect of everolimus would last following treat-
ment cessation.
Discussion
In the present study, we describe a case of a Korean
family in which three of the members have been diag-
nosed with TSC. Among the affected members, only a
boy (III-2 in Fig. 2a) showed diverse behavioral and cog-
nitive deficits including autistic phenotypes. Whole ex-
ome analysis revealed a novel deletion mutant in the
TSC2 gene (TSC2 c.700–701 del).
We found that the expression of the newly identified
mutant TSC2 protein enhanced the activation of the
mTOR signaling pathway in HEK293T cells, suggesting
that the novel mutation represents a loss-of-function
mutation as are other TSC mutations associated with
TSC [28]. In our biochemical analyses, we found that
the protein expression level of the deletion mutant was
significantly decreased (Fig. 3a, b). The reduced TSC2
c.700–701 del mutant expression level might be caused
by nonsense-mediated mRNA decay as a quality-control
mechanism [35–37]. In addition, it has been reported
that the TSC1-TSC2 interaction is important for stability
of both TSC1 and TSC2 [38, 39]. In this patient, it is hy-
pothesized that the TSC1 protein would be destabilized
since the mutation in TSC2 is located within the essen-
tial region for interacting with TSC1 (amino acids 1–
900) [31, 40] (Fig. 3a, c). Furthermore, the loss of the C-
terminal GTPase activating protein (GAP) domain of
TSC2 would also be predicted to disrupt the action of
the TSC1-TSC2 complex on the GTPase Ras homolog
expressed in brain (RHEB), thus activating RHEB–GTP-
dependent stimulation of the mammalian target of rapa-
mycin complex 1 (mTORC1) [41]. Therefore, one of the
downstream mTORC1 targets, S6K T389 phosphoryl-
ation, would be elevated (Fig. 3a, d). Additionally, we
examined the effect of everolimus treatment on elevated
S6K T389 phosphorylation induced by TSC2 c.700–701
del mutation and found that everolimus could reduce
the activation of the mTOR signaling pathway (Fig. 4a,
b).
The efficacy of mTOR inhibitors for treating TSC-
associated phenotypes has been demonstrated in mul-
tiple animal models. For example, Ehninger and
colleagues showed that rapamycin treatment reversed
the deficits in learning and in hippocampal synaptic
plasticity in Tsc2+/− mice [18]. Rapamycin or everolimus
(RAD001, 40-O-(2-hydroxyethyl)-rapamycin) treatment
rescued lethality, brain enlargement, and hyperactivity in
Tsc1 conditional knockout mice [18, 19]. Notably, delet-
ing Tsc1 in mouse cerebellar Purkinje cells resulted in
autistic-like behaviors, which can also be reversed by
rapamycin treatment [20]. In addition, deficits in social
interaction in Tsc1+/− and Tsc2+/− mice were also re-
versed by rapamycin treatment [26]. These animal stud-
ies support the hypothesis that mTOR activation is
responsible for the ASD-associated phenotypes in TSC
[16, 26, 42] and thereby mTOR inhibition might be an
effective treatment strategy for ASD symptoms in TSC
patients [10, 25].
In our study, everolimus treatment resulted in a rapid
and marked reduction of behavioral deficits and im-
proved cognition, attention, social interaction, and lan-
guage development in the patient. As indicated by
changes in the ATEC subscale scores, the classification
of severe autism with scores in the 90th percentile was
modified to that of semi-independent autism with scores
in the 30th percentile level. The total score dropped by
83 points, which is considered to be a remarkable im-
provement for an autism treatment. In addition to the
improvement of autistic features, everolimus showed
marked effectiveness in mediating the intractable sei-
zures of TSC, such that the seizure frequency and the
median seizure duration decreased by over 90 % in the
patient. However, we cannot insist that everolimus
would have therapeutic effect specifically on ASD or epi-
lepsy in patients with TSC induced by TSC2 c.700–701
del mutation because grandmother and father carrying
TSC2 c.700–701 del mutation has normal intelligence
without epilepsy or neuropsychiatric symptoms and we
could not suggest an evidence of genotype (TSC2 c.700–
701 del mutation)-phenotype correlation in TSC patient.
Therefore, we consider that individuals affected by TSC2
c.700–701 del mutation could exhibit a high variability
in clinical findings and further studies are needed to
identify a key mechanism underlying the therapeutic
effect of everolimus on TSC symptoms with ASD.
Nevertheless, early recognition of ASD in patients with
TSC and proper management with everolimus might give
a life-enhancing effect on the long-term outcome of the
disorder. Consistent with our findings, Ishii and colleagues
recently reported that everolimus treatment improved the
irritability, stereotypic behavior, inappropriate speech, and
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social behavior in a 27 year-old female patient with TSC
[43]. In addition, Wheless showed that everolimus re-
duced the seizure frequency in a 13-year-old girl with
TSC-associated epilepsy after 1.5 years of treatment [44].
Kruger and colleagues also demonstrated the antiepileptic
effect of everolimus in the majority of TSC patients [45].
Focal cortical malformations such as cortical tuber are
highly associated with epileptogenesis and epilepsy related
to cortical tuber is often refractory to antiepileptics [46].
mTOR inhibitor treatment also reduces the size of cortical
tubers in TSC patients [47].
Together with our results, these studies strongly sup-
port that the inhibition of mTOR signaling represents a
valid treatment strategy for the neurological and psychi-
atric manifestations associated with TSC. As additional
clinical trials to test the efficacy of everolimus for treat-
ing the psychiatric symptoms associated with TSC have
been completed or launched [10, 17], it will likely soon
be determined whether the use of everolimus or other
mTOR inhibitors will be approved to treat the features
of ASD associated with TSC in the clinic.
In summary, we identified a novel small deletion muta-
tion in TSC2 associated with severe TSC in a Korean fam-
ily that enhances the activation of mTOR signaling in
vitro. Moreover, everolimus treatment showed not only
reduction in SEGA size, but improved behavioral deficits
including autistic phenotypes and seizures in the patient.
Methods
Participants
The study participants consisted of a three-generation
family whose members were diagnosed with TSC. TSC
showed autosomal dominant inheritance throughout the
family history; the grandmother was the first affected
family member. Six individuals including the grand-
mother, father, mother, second and third sons, and
daughter participated in this study.
Diagnostic evaluation
Diagnosis of TSC
Brain MRI, EEG, complete ophthalmologic evaluation in-
cluding dilated fundoscopy, detailed dental examination,
careful skin examination with a Wood’s lamp, ultrasonog-
raphy and ECG of the heart, HRCT of the chest, blood
pressure, abdominal MRI, and GFR tests were performed.
In addition to genetic diagnosis (described below), clinical
diagnosis was made according to the “Tuberous Sclerosis
Complex Diagnostic Criteria Update: Recommendations
of the 2012 International Tuberous Sclerosis Complex
Consensus Conference” [48].
Measures and procedure
A baseline psychomotor developmental evaluation in-
cluding the DDST-II, WPPSI-III, CARS, SMS, and
speech and language evaluations was performed prior to
everolimus treatment. The ADOS and ADI-R were con-
ducted by an experienced examiner. For ADOS, module
1 for 31 months and older children with pre-verbal/sin-
gle words was applied. The ATEC was also implemented
for the severity evaluation of autistic features prior to
and following completion of the intervention.
Intervention
Everolimus treatment was initiated, at 5 mg/m2/day, ad-
ministered once daily in the morning and rounded to
the nearest 2.5 mg/dose. A serum everolimus level was
obtained at every 2 weeks, and the treatment dose was
adjusted to obtain a target range between 5 and 15 ng/
ml. No further adjustments were made after the stable
target range was obtained, unless a severe side effect or
considerable weight gain was noticed. Safety and efficacy
of treatment was observed for 1 year.
Whole exome sequencing and variant calling
Whole blood was obtained from the family members
(the grandmother, father, mother, elder brother, and little
sister of the patient) after informed consent for the
protocol (KNUH 2013-07-011-004) guided by the
KNUH IRB was obtained. Genomic DNA was extracted
from the blood from each subject and about 3 μg gen-
omic DNA from each family member was subjected to
library preparation and exome capture following the
Agilent SureSelect Human All Exon v4 Illumina Paired-
End Sequencing Library Prep Protocol (Agilent Tech-
nologies, Santa Clara, CA, USA). The prepared sequen-
cing library was used to perform sequencing on an
Illumina HiSeq-2000 system (San Diego, CA, USA) as a
100 bp paired-end run. In each sample, about 51–65
million reads were generated. The raw sequencing reads
were checked and trimmed using the sickle program
(version 1.33) to ensure the quality of the raw reads.
Processed reads were mapped to the reference human
genome sequence GRCh37 using the Burrow-Wheeler
Aligner (BWA, version 0.7.10) [49]. To reduce the po-
tential bias problems caused by the sequencing pro-
cesses, the mapped duplicated reads were marked using
Picard (version 1.118). Insertion and realignment
(INDEL) realignment and base quality recalibration were
performed using GATK (version 3.2.2) [50]. The average
of the mean target coverage was 65 and 85 % of the tar-
get exome was covered to 20×. Using the alignments,
both small nucleotide variants (SNVs) and small INDELs
were called by the GATK HaplotypeCaller and called
variants were filtered using the GATK variant quality
score recalibration process. Finally, for each family
member, 84,356–86,901 variants were obtained. The var-
iants were further filtered to exclude those included in
dbSNP142, 1000 Genomes Project (Oct 2014), NHLBI-
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ESP project with 6500 exomes, or ExAC 65,000 exomes
at the level of 5 % minor allele frequency (MAF) by
ANNOVAR [51]. In addition, variants were filtered out
if they existed in in-house genome and exome databases.
Sanger sequencing
To validate the small deletion variant in the TSC2 gene,
Sanger sequencing was performed. The target site of the
variant and the flanking sequences of the DNA template
from each family member were amplified with specific
primers (forward primer 5′-ACAGTGACAGGGACGT-
CAGGTG-3′ and reverse primer 5′-ACAACCATT-
CATGGGAGACAGGA-3′) and the amplified products
were directly sequenced on an ABI PRISM 3730 automated
sequencer (Applied Biosystems, Foster City, CA, USA).
The results were compared with the reference human gen-
ome sequence, GRCh37, to confirm the deletion variant.
DNA constructs
Full-length TSC1 with a Myc-tag at the C-terminus, wild-
type TSC2, and the pathogenic TSC2 mutation p.R611Q
were kindly provided by Dr. Mark Nellist (Eramus Med-
ical Centre, The Netherlands). pcDNA-Myc S6K1 was a
gift from Jie Chen (Addgene plasmid #26610, Cambridge,
MA, USA) [52]. The novel TSC2 c.700–701 deletion con-
struct was derived from the wild-type TSC2 construct by
site-directed mutagenesis using a QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA). N-terminal HA-tagged wild-type TSC2, TSC2
p.R611Q, and TSC2 c.700–701 deletion mutants were
subcloned into the pcDNA3.1(+) vector using BamHI and
XhoI sites. The complete open reading frame of the each
construct was verified by sequencing. Construct DNA
were prepared using the PureYield™ Plasmid Midiprep
System (Promega, Madison, WI, USA).
Antibodies
Phospho-p70 S6 kinase Thr389 rabbit monoclonal
(108D2 for Fig. 3 or 9205S for Fig. 4), Myc-tag mouse
monoclonal (9B11), and HRP-conjugated anti-rabbit IgG
(#7074) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). HRP-conjugated goat
anti-rat IgG (#AP183P), HRP-conjugated anti-mouse
IgG (H+L) (#SA001-500), and anti-HA-Fluorescein, high
affinity (#11 988 506 001) antibodies were obtained from
Millipore (Darmstadt, Germany), GenDEPOT (Barker,
TX, USA), and Roche (Basel, Switzerland), respectively.
Immunoblotting
A transfection-based immunoblot assay for the
functional assessment of the TSC2 variants was per-
formed as described previously [30, 31]. HEK293T cells
were plated on a 12-well plate and grown overnight in
Dulbecco’s modified eagle’s medium (DMEM) (Hyclone,
Logan, UT, USA) with 10 % fetal bovine serum (FBS).
Confluent cells (70–90 %) were transfected with 0.4 μg
TSC2, 0.8 μg TSC1, and 0.2–0.3 μg S6K1 constructs
using 4 μL Lipofectamine® 2000 (Thermo Fisher Scien-
tific, Waltham, MA, USA) in Opti-MEM. The trans-
fected medium was replaced with DMEM with 10 % FBS
at 4 h after transfection. And then, everolimus (10 nM,
LC Laboratories, Woburn, MA, USA) was added and in-
cubated for another 20 h. The transfected cells were har-
vested, washed with cold phosphate-buffered saline, and
lysed with 200 μL RIPA buffer (150 mM NaCl, 1.0 %
Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS,
and 50 mM Tris-Cl, pH 8.0) containing a protease in-
hibitor cocktail and a phosphatase inhibitor cocktail
(Roche). After full-speed centrifugation for 15 min at 4 °C,
the supernatant fractions were quantified using a Thermo
Scientific™ Pierce™ BCA Protein Assay kit. The protein
samples (4.5 μg each) were electrophoresed on Bolt® 4–
12 % Bis-Tris Plus Gels (Thermo Fisher Scientific) and
transferred to PVDF membranes (Millipore) according to
the manufacturer’s recommendations.
The blots were blocked for 10 min at room temperature
with either 5 % Blotto, non-fat dry milk (sc-2325, Santa
Cruz Biotechnology, Dallas, TX, USA) or 5 % bovine
serum albumin in TBST (Tris-buffered saline plus 0.1 %
Tween-20). Blots were incubated overnight at 4 °C with
the following primary antibodies: 1:1000 dilutions of
rabbit monoclonal anti-p-S6K (T389) or rat anti-HA anti-
body, or 1:10,000 dilutions of mouse monoclonal anti-myc
tag antibody. After washing three times for 10 min in
TBST, the blots were incubated for 2 h at room
temperature with 1:5000 dilutions of secondary antibodies.
After washing three times for 10 min in TBST, the blots
were scanned using a ChemiDoc™ XRS System (Bio-Rad,
Hercules, CA, USA) after applying detection reagents. To
estimate the ratio of p-S6K (T389) to total S6K, the scans
were analyzed using Image Lab™ Software (Bio-Rad).
Statistics
One-way analysis of variance (ANOVA) with appropriate
post-hoc tests (Dunnett’s or Bonferroni’s test) was used
for western blotting results. Each “n” indicates an inde-
pendent set of experiment. Differences are considered sig-
nificant at the level of p <0.05.
Additional file
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